MedTrace Logo

Study of AK119 in Subjects With Advanced Solid Tumors

NCT05173792 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-04-25

No results posted yet for this study

Summary

This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.

Conditions

Interventions

DRUG

AK119

Subjects will receive AK119 intravenously.

Sponsors & Collaborators

Principal Investigators

  • Jihui Hao, PhD · Tianjin Medical University Cancer Insitute & Hospital

  • Tianshu Liu · Shanghai Zhongshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2023-05-22
Completion
2023-05-22

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05173792 on ClinicalTrials.gov